ライフサイエンスコーパス: inoperable

1 e options for patients previously considered inoperable.

2 and are found to be either inappropriate or inoperable.

3 tan in 80 patients with CTEPH adjudicated as inoperable.

4 mitral regurgitation deemed at high risk or inoperable.

5 stenosis who are at a 'high risk' or deemed inoperable.

6 ber 2013 and September 2014, 583 HR (65%) or inoperable (35%) patients were treated via the transfemo

7 Overall Outcome: 51 patients were inoperable, 92 were subjected to exploration and biopsy

8 polymer electrolyte membrane fuel cells are inoperable above 100 degrees C, require cumbersome humid

9 tive ALCL and 14 patients with metastatic or inoperable ALK-positive IMT received crizotinib orally t

10 ent TAVR included 1559 (20%) cases that were inoperable and 6151 (80%) cases that were high-risk but

11 Right from the start of Imatinib therapy in inoperable and disseminated GIST patients, specific CT i

12 For patients who are inoperable and have chronic thromboembolic pulmonary hyp

13 d improve the cost-effectiveness of TAVR for inoperable and high-risk patients, but reductions in the

14 ents treated electively, 25% were considered inoperable, and 27% were considered high risk for bypass

15 Most cases are inoperable, and biopsies to investigate SCLC biology are

16 mediastinum, the patient's cancer was deemed inoperable, and he was referred for consideration of con

17 s, is recommended in patients who are deemed inoperable, and is a reasonable alternative to surgical

18 ents with liver metastases were often deemed inoperable, and medical therapy conferred only minor sur

19 a total of 419 patients (177 from cohort B [inoperable] and 242 from cohort A [operable high-risk])

20 We enrolled patients with severe symptomatic inoperable aortic stenosis and randomly assigned (1:1) t

21 ve options for access sites in patients with inoperable aortic stenosis who are ineligible for TF TAV

22 ial than standard treatment for treatment of inoperable aortic stenosis.

23 s with far advanced disease, once considered inoperable, are now often helped substantially by valve

24 Patients were studied from the inoperable arm (cohort B) of the randomized PARTNER (Pla

25 In inoperable AS patients, TAVR substantially reduced the r

26 selected for surgery versus SBRT (medically inoperable) at physician discretion, OS was higher in su

27 AVR) for patients who were deemed surgically inoperable BACKGROUND: Data and experience with TAVI in

28 Smoothened antagonists, in the treatment of inoperable BCC.

29 approximately 30% to 50% of these tumors are inoperable because of their localization in highly eloqu

30 ents are ineffective and some tumours remain inoperable because of their size or location.

31 Axons of diameter below 0.1 microm become inoperable because single, spontaneously opening Na chan

32 cuses on four subgroups (stage IV, initially inoperable, bilateral, and relapsed WT) for which intern

33 n the symptomatic treatment of patients with inoperable bowel obstruction due to peritoneal carcinoma

34 lly those who are deemed either high risk or inoperable by the usual surgical standards.

35 ncer after surgery, and (3) locally advanced inoperable cancer.

36 balloon test occlusions in 44 patients with inoperable carotid cavernous aneurysms or head and neck

37 stent patency and survival in patients with inoperable cholangiocarcinoma treated with Gianturco met

38 tudy, we randomly assigned 261 patients with inoperable chronic thromboembolic pulmonary hypertension

39 diagnosed pulmonary arterial hypertension or inoperable chronic thromboembolic pulmonary hypertension

40 as technically inoperable (TI) or clinically inoperable (CLI).

41 ranscatheter aortic valve replacement (TAVR; inoperable cohort) and surgical aortic valve replacement

42 tic Transcatheter Valves (PARTNER) II trial (inoperable cohort) with a Sapien or Sapien XT valve via

43 In the inoperable cohort, patients with LF had higher mortality

44 efits compared with standard therapy in both inoperable cohorts.

45 46 of whom had cardiomyopathy and 18 who had inoperable complex congenital heart disease, underwent c

46 ren with end-stage heart failure or complex, inoperable congenital cardiac defects.

47 scularization for the treatment of otherwise inoperable coronary artery disease has increased rather

48 heart failure, surgery for vascular disease, inoperable coronary disease, and amputation for ischemic

49 significantly improved PVR in patients with inoperable CTEPH and was well tolerated.

50 rity and long-term outcomes in patients with inoperable CTEPH or persistent or recurrent pulmonary hy

51 For patients with inoperable CTEPH, various medical and interventional the

52 ocally advanced basal-cell carcinoma who had inoperable disease or for whom surgery was inappropriate

53 rding SEMS as sole therapy for patients with inoperable disease who have not already received, or are

54 erapeutic intervention against aggressive or inoperable disease.

55 available treatment options for recurrent or inoperable disease.

56 lity of life improvements than those who are inoperable due to clinical comorbidities.

57 g cancer (NSCLC); however, many patients are inoperable due to comorbid diseases.

58 ts with severe aortic stenosis may be deemed inoperable due to technical or clinical reasons.

59 ent options, the prognosis for patients with inoperable esophageal carcinoma is still poor and the re

60 enosis (AS) who were deemed too high risk or inoperable for conventional aortic valve replacement (AV

61 Of the 369 patients, 23.0% were considered inoperable for technical reasons alone; the remaining we

62 ion SBRT for initial treatment of localized, inoperable HCC is not cost-effective.

63 Thirty-eight patients with inoperable HCC underwent 1.5-T MR imaging, including DW

64 Patients with inoperable HCC, no prior systemic treatment, and Child-P

65 RT are effective local treatment options for inoperable HCC.

66 TACE is an effective treatment for inoperable hepatic tumors, especially hypervascular tumo

67 tion (IRE) in the treatment of patients with inoperable hepatocellular carcinoma (HCC) who are inelig

68 Four patients with inoperable hepatocellular carcinoma were treated with a

69 analysis of our early clinical outcomes for inoperable hepatocellular carcinoma.

70 s catheter-based therapies for patients with inoperable hepatocellular carcinoma.

71 ement has become the procedure of choice for inoperable, high-risk, and many intermediate-risk patien

72 Seventy-nine consecutive patients with inoperable IHCC were identified and treated with definit

73 of higher doses of RT improves LC and OS in inoperable IHCC.

74 Some arteriovenous malformations considered inoperable in the past can now be successfully treated u

75 of intracellular S-100B, and this pathway is inoperable in the S-100B KO (-/-).

76 smic reticulum Ca2+ pool depletion, which is inoperable in WEHI7.2 cells, and one in response to glyc

77 Standard therapies for localized inoperable intrahepatic cholangiocarcinoma (IHCC) are in

78 s to be a reasonable first-line treatment of inoperable, larger HCC.

79 dian survival is only 6 months in those with inoperable lesions.

80 treatment option for pediatric patients with inoperable LGG WHO grades I and II.

81 chemotherapy was conducted in patients with inoperable liver metastases from CRC who had not previou

82 iofrequency ablation (RFA) for patients with inoperable localized hepatocellular carcinoma (HCC) who

83 Markov model was developed for patients with inoperable, localized HCC who were eligible for both RFA

84 an integrated therapeutic approach to treat inoperable locally advanced breast cancer.

85 ted therapies are available in patients with inoperable locally advanced cutaneous squamous cell carc

86 uman epidermal growth factor (HER2)-negative inoperable locally advanced or metastatic breast cancer

87 se 2 trial, patients (aged >/=18 years) with inoperable locally advanced or metastatic urothelial car

88 n radiotherapy (CIRT) holds promise to treat inoperable locally-advanced non-small cell lung carcinom

89 omen aged 18 years or older with measurable, inoperable, locally advanced or metastatic triple-negati

90 ely, >80% of pancreatic cancer patients bear inoperable, locally advanced, chemoresistant tumors demo

91 , chemotherapy is the standard treatment for inoperable, locally advanced, non-metastatic pancreatic

92 Patients with early stage but medically inoperable lung cancer have a poor rate of primary tumor

93 priate support may have a negative impact on inoperable lung cancer patients.

94 ndomized controlled trial, 115 patients with inoperable lung cancer were randomly assigned to receive

95 metastatic disease, and seven patients with inoperable lung cancer.

96 rs) with 189 primary or metastatic medically inoperable lung cancers underwent percutaneous fluorosco

97 80 patients with peritoneal carcinomatosis, inoperable malignant digestive obstruction, and two or m

98 -radiotherapy treatment 1.5 years ago due to inoperable mass in the mid-lower pole of the left kidney

99 ollected database included 222 patients with inoperable MBO treated by PTBS with uncovered nitinol SE

100 randomized clinical trial, 55 patients with inoperable mCRC and prior stable disease after standard

101 clinical problem, because it often involves inoperable metastatic disease.

102 n 89 patients with histologically confirmed, inoperable metastatic gastroenteropancreatic NENs underg

103 ed the prognostic impact of (18)F-FDG PET in inoperable multifocal disease.

104 portant recent advances in the management of inoperable non--small cell lung cancer.

105 Eleven patients with inoperable non-small cell lung cancer underwent 2-5 thor

106 Patients with inoperable non-small cell lung cancer who received stere

107 improving the outcome for locally advanced, inoperable non-small cell lung cancer.

108 ekly carboplatin/paclitaxel chemotherapy for inoperable non-small-cell lung cancer (NSCLC).

109 Patients with locally advanced or medically inoperable non-small-cell lung cancer received three-dim

110 therapy, the mainstay of treatment for early inoperable non-small-cell lung cancer, is most commonly

111 with PE/XRT alone in patients with stage III inoperable NSCLC.

112 ons after SEMS placement as sole therapy for inoperable oesophageal cancer in a resource-limited sett

113 Therapies for inoperable oesophageal cancer include chemoradiotherapy

114 ed when SEMS are placed in all patients with inoperable oesophageal cancer, as in our study, rather t

115 SEMS effectively palliate inoperable oesophageal cancer.

116 odynamic therapy are potential therapies for inoperable or advanced pancreatic cancer.

117 oach for patients with DMS who are otherwise inoperable or at high risk for surgery.

118 ty-six percent of these patients were deemed inoperable or at high surgical risk.

119 local therapy for tumors that are surgically inoperable or difficult to treat systemically.

120 ass surgery, previous myocardial infarction, inoperable or high surgical risk or multivessel disease

121 (TAVI) is an advancing mode of treatment for inoperable or high-risk patients with aortic stenosis.

122 The approach can be used to treat inoperable or incompletely removed tumors by situating i

123 atment for patients with well-differentiated inoperable or metastatic NETs and disease progression af

124 ptor radionuclide therapy is a treatment for inoperable or metastatic neuroendocrine tumors.

125 el study is being conducted in patients with inoperable or metastatic solid tumors.

126 Patients with inoperable or unresectable pancreatic neuroendocrine tum

127 mic medical centers with 42 patients who had inoperable or unresectable stage II to stage III NSCLC e

128 dicine has had little to offer patients with inoperable pancreatic adenocarcinoma; thus, many patient

129 Of 55 patients who had inoperable pancreatic cancer, 23 elected gemcitabine-bas

130 he pooled outcomes for all randomly assigned inoperable patients (n=449) in PARTNER, as well, includi

131 s excellent 1-year survival in high-risk and inoperable patients is achievable and provides a benchma

132 he standard of care for severely symptomatic inoperable patients or those at high risk of noncardiova

133 In inoperable patients treated with transcatheter aortic va

134 tinum agent remains the standard of care for inoperable patients who have metastatic or recurrent dis

135 placement as the preferred therapy in HR and inoperable patients with aortic stenosis.

136 placebo-controlled, dose-escalating study of inoperable patients with class III or IV angina.

137 scatheter aortic valve replacement (TAVR) in inoperable patients with severe aortic stenosis remain u

138 aseline renal impairment among high-risk and inoperable patients with severe aortic stenosis undergoi

139 in better survival and functional status in inoperable patients with severe aortic stenosis with dur

140 Conclusions- Among inoperable patients with severe aortic stenosis, compare

141 TAVR is attractive in high-risk or inoperable patients with severe aortic stenosis.

142 achieved with this SBRT regimen in medically inoperable patients with stage I NSCLC.

143 485 230 (95% CI, 284 550-66 7350) high-risk/inoperable patients, 152 690 (95% CI, 73 410-263 000) in

144 ents until it became the default therapy for inoperable patients, and a recommended therapy in high-r

145 tic valve replacement for high-risk (HR) and inoperable patients, mortality at 1 year was 24% in HR a

146 rge, adjudicated registry of SAPIEN 3 HR and inoperable patients, the very low rates of important com

147 y also be appropriate for highly symptomatic inoperable patients.

148 mortality at 1 year was 24% in HR and 31% in inoperable patients.

149 be clinically improved by medical therapy in inoperable patients.

150 overall level of immune dysfunction in these inoperable patients.

151 t children with neurofibromatosis type 1 and inoperable plexiform neurofibromas benefited from long-t

152 hildren who had neurofibromatosis type 1 and inoperable plexiform neurofibromas to determine the maxi

153 Thirty-five patients (16%) had multiple inoperable PM and required the HR protocol.

154 Malignant osteolysis associated with inoperable primary bone tumors and multifocal skeletal m

155 dergone orthotopic heart transplantation for inoperable primary cardiac tumors.

156 Material/CT studies of 14 patients with inoperable primary tumors and 56 patients with metastati

157 phase III study, a total of 52 patients with inoperable progressive skin lesions from histologically

158 G) is clinically used as an antiandrogen for inoperable prostate cancer, virilizing syndromes in wome

159 The most common principal causes were inoperable retinal detachment (n = 7, 36.8%), terminal g

160 pic vitrectomy was done in them to detect an inoperable retinal detachment in 1 eye.

161 Forty-four consecutive patients with inoperable, severe aortic stenosis underwent TAO TAVR in

162 The optimal treatment for medically inoperable stage I non-small-cell lung cancer (NSCLC) ha

163 tereotactic ablative radiotherapy (SABR) for inoperable stage I NSCLC has shown promising results, bu

164 Thirty-nine patients with inoperable stage II or III NSCLC, treated with chemoradi

165 feasible and highly active in patients with inoperable stage III lung cancer.

166 rapy is standard treatment for patients with inoperable stage III non-small-cell lung cancer (NSCLC).

167 Two hundred eighty-three patients with inoperable stage III non-small-cell lung cancer were ent

168 concurrent chemoradiation for patients with inoperable stage III non-small-cell lung cancer.

169 Patients with inoperable stage III or IV non-small-cell lung cancer an

170 (PAC) is often diagnosed at an advanced and inoperable stage, and standard systemic treatments are g

171 t of severe, symptomatic aortic stenosis and inoperable status (in 2011) and high-risk but operable s

172 , 87.3% in the HR subgroup, and 82.3% in the inoperable subgroup.

173 to patients considered to be high risk or to inoperable surgical candidates.

174 n, or for those whose tumors are considered "inoperable." Technical advances, including intraoperativ

175 se for radioiodine-refractory and surgically inoperable thyroid cancers as shown in clinical trials;

176 whether they were classified as technically inoperable (TI) or clinically inoperable (CLI).

177 nt (SAVR); (n = 138); and Cohort B patients (inoperable) treated by either TAVR (n = 72) or standard

178 ry may provide a viable treatment option for inoperable tumors and reduce the rate of metastatic rela

179 th nonmetastatic disease, because it renders inoperable tumors operable and increases the rates of br

180 RE) is a promising non-thermal treatment for inoperable tumors which uses short (50-100 mus) high vol

181 es mandates further studies in patients with inoperable tumors who will receive CTL102 and CB1954.

182 rapy have been ineffective for patients with inoperable tumours.

183 metal complexes, this reaction has appeared inoperable with aliphatic substrates.

184 of those receiving SBRT, 95% were medically inoperable, with 5% refusing surgery.